Phillip Md Et Al Frost Purchases 55,000 Shares of Opko Health Inc. (OPK) Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 55,000 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were acquired at an average price of $4.30 per share, for a total transaction of $236,500.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $13,196,489.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, February 5th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were acquired at an average price of $4.14 per share, for a total transaction of $207,000.00.
  • On Wednesday, January 31st, Phillip Md Et Al Frost bought 65,000 shares of Opko Health stock. The stock was purchased at an average price of $4.47 per share, for a total transaction of $290,550.00.
  • On Friday, January 26th, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The stock was purchased at an average price of $4.90 per share, for a total transaction of $269,500.00.
  • On Wednesday, January 24th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was purchased at an average price of $4.89 per share, for a total transaction of $489,000.00.
  • On Monday, January 22nd, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was purchased at an average price of $4.40 per share, for a total transaction of $440,000.00.

Shares of Opko Health Inc. (OPK) opened at $4.14 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.48. Opko Health Inc. has a 52-week low of $4.01 and a 52-week high of $8.92. The company has a market capitalization of $2,427.82, a P/E ratio of -18.82 and a beta of 1.42.

Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The company had revenue of $263.50 million during the quarter, compared to analysts’ expectations of $319.43 million. During the same quarter in the prior year, the company posted ($0.03) EPS. The company’s revenue for the quarter was down 11.6% on a year-over-year basis. sell-side analysts forecast that Opko Health Inc. will post -0.27 earnings per share for the current year.

A number of equities research analysts recently commented on OPK shares. Cantor Fitzgerald set a $20.00 target price on Opko Health and gave the company a “buy” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Finally, BidaskClub lowered Opko Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $13.34.

A number of institutional investors have recently added to or reduced their stakes in OPK. Crossmark Global Holdings Inc. acquired a new position in shares of Opko Health during the 3rd quarter worth approximately $118,000. The Manufacturers Life Insurance Company raised its stake in shares of Opko Health by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,657 shares during the period. Psagot Investment House Ltd. raised its stake in shares of Opko Health by 20.0% during the 2nd quarter. Psagot Investment House Ltd. now owns 22,862 shares of the biotechnology company’s stock worth $150,000 after buying an additional 3,806 shares during the period. Prudential Financial Inc. raised its stake in shares of Opko Health by 6.1% during the 2nd quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock worth $161,000 after buying an additional 1,400 shares during the period. Finally, State of Alaska Department of Revenue acquired a new position in shares of Opko Health during the 4th quarter worth approximately $144,000. Institutional investors and hedge funds own 22.94% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Phillip Md Et Al Frost Purchases 55,000 Shares of Opko Health Inc. (OPK) Stock” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://sportsperspectives.com/2018/02/08/phillip-md-et-al-frost-purchases-55000-shares-of-opko-health-inc-opk-stock.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply